155 related articles for article (PubMed ID: 19104789)
1. eNOS T-786C polymorphism affects atorvastatin-induced changes in erythrocyte membrane fluidity.
Nagassaki S; Herculano RD; Graeff CF; Tanus-Santos JE
Eur J Clin Pharmacol; 2009 Apr; 65(4):385-92. PubMed ID: 19104789
[TBL] [Abstract][Full Text] [Related]
2. eNOS gene T-786C polymorphism modulates atorvastatin-induced increase in blood nitrite.
Nagassaki S; Sertório JT; Metzger IF; Bem AF; Rocha JB; Tanus-Santos JE
Free Radic Biol Med; 2006 Oct; 41(7):1044-9. PubMed ID: 16962929
[TBL] [Abstract][Full Text] [Related]
3. Anti-inflammatory effects of atorvastatin: modulation by the T-786C polymorphism in the endothelial nitric oxide synthase gene.
Souza-Costa DC; Sandrim VC; Lopes LF; Gerlach RF; Rego EM; Tanus-Santos JE
Atherosclerosis; 2007 Aug; 193(2):438-44. PubMed ID: 16938300
[TBL] [Abstract][Full Text] [Related]
4. Effects of atorvastatin and T-786C polymorphism of eNOS gene on plasma metabolic lipid parameters.
Zago VH; Santos JE; Danelon MR; Silva RM; Panzoldo NB; Parra ES; Alexandre F; Virgínio VW; Quintão EC; Faria EC
Arq Bras Cardiol; 2013 Jan; 100(1):14-20. PubMed ID: 23250834
[TBL] [Abstract][Full Text] [Related]
5. Physicochemical modifications induced by statins therapy on human erythrocytes membranes.
Broncel M; Bała A; Koter-Michalak M; Duchnowicz P; Wojsznis W; Chojnowska-Jezierska J
Wiad Lek; 2007; 60(7-8):321-8. PubMed ID: 18175550
[TBL] [Abstract][Full Text] [Related]
6. The effect of atorvastatin on erythrocyte membranes and serum lipids in patients with type-2 hypercholesterolemia.
Koter M; Broncel M; Chojnowska-Jezierska J; Klikczynska K; Franiak I
Eur J Clin Pharmacol; 2002 Nov; 58(8):501-6. PubMed ID: 12451426
[TBL] [Abstract][Full Text] [Related]
7. The effects of atorvastatin therapy on rheological characteristics of erythrocyte membrane, serum lipid profile and oxidative status in patients with dyslipidemia.
Uydu HA; Yıldırmış S; Orem C; Calapoglu M; Alver A; Kural B; Orem A
J Membr Biol; 2012 Nov; 245(11):697-705. PubMed ID: 22706680
[TBL] [Abstract][Full Text] [Related]
8. Atorvastatin upregulates type III nitric oxide synthase in thrombocytes, decreases platelet activation, and protects from cerebral ischemia in normocholesterolemic mice.
Laufs U; Gertz K; Huang P; Nickenig G; Böhm M; Dirnagl U; Endres M
Stroke; 2000 Oct; 31(10):2442-9. PubMed ID: 11022078
[TBL] [Abstract][Full Text] [Related]
9. [Erythrocyte fluidity in patients with hyperlipidemia during statins therapy].
Broncel M; Chojnowska-Jezierska J; Koter-Michalak M; Franiak I
Pol Arch Med Wewn; 2005 Jun; 113(6):531-7. PubMed ID: 16454441
[TBL] [Abstract][Full Text] [Related]
10. Critical promoter region for statin-induced human endothelial nitric oxide synthase (eNOS) transcription in EA.hy926 cells.
Mashimo Y; Ishikawa T; Numakura M; Kinoshita M; Teramoto T
J Atheroscler Thromb; 2013; 20(4):321-9. PubMed ID: 23258079
[TBL] [Abstract][Full Text] [Related]
11. Atorvastatin restores endothelial function in normocholesterolemic smokers independent of changes in low-density lipoprotein.
Beckman JA; Liao JK; Hurley S; Garrett LA; Chui D; Mitra D; Creager MA
Circ Res; 2004 Jul; 95(2):217-23. PubMed ID: 15178637
[TBL] [Abstract][Full Text] [Related]
12. A pharmacogenetics-based approach to reduce cardiovascular mortality with the prophylactic use of statins.
Lacchini R; Silva PS; Tanus-Santos JE
Basic Clin Pharmacol Toxicol; 2010 May; 106(5):357-61. PubMed ID: 20210789
[TBL] [Abstract][Full Text] [Related]
13. Hydroxy-methylglutaryl-coenzyme A reductase inhibition promotes endothelial nitric oxide synthase activation through a decrease in caveolin abundance.
Feron O; Dessy C; Desager JP; Balligand JL
Circulation; 2001 Jan; 103(1):113-8. PubMed ID: 11136695
[TBL] [Abstract][Full Text] [Related]
14. Atorvastatin delays murine platelet activation in vivo even in the absence of endothelial NO synthase.
Ni R; Peleg T; Gross PL
Arterioscler Thromb Vasc Biol; 2012 Nov; 32(11):2609-15. PubMed ID: 22995523
[TBL] [Abstract][Full Text] [Related]
15. Influence of microsomal triglyceride transfer protein promoter polymorphism -493 GT on fasting plasma triglyceride values and interaction with treatment response to atorvastatin in subjects with heterozygous familial hypercholesterolaemia.
García-García AB; González C; Real JT; Martín de Llano JJ; González-Albert V; Civera M; Chaves FJ; Ascaso JF; Carmena R
Pharmacogenet Genomics; 2005 Apr; 15(4):211-8. PubMed ID: 15864113
[TBL] [Abstract][Full Text] [Related]
16. Atorvastatin protects obese mice against hepatic ischemia-reperfusion injury by Toll-like receptor-4 suppression and endothelial nitric oxide synthase activation.
Ajamieh H; Farrell G; Wong HJ; Yu J; Chu E; Chen J; Teoh N
J Gastroenterol Hepatol; 2012 Aug; 27(8):1353-61. PubMed ID: 22432744
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the effects of rosuvastatin monotherapy and atorvastatin-ezetimibe combined therapy on the structure of erythrocyte membranes in patients with coronary artery disease.
Olszewska-Banaszczyk M; Jackowska P; Gorzelak-Pabiś P; Pytel E; Koter-Michalak M; Broncel M
Pharmacol Rep; 2018 Apr; 70(2):258-262. PubMed ID: 29475008
[TBL] [Abstract][Full Text] [Related]
18. Association of endothelial nitric oxide synthase promoter region (T-786C) gene polymorphism with acute coronary syndrome and coronary heart disease.
Ciftçi C; Melil S; Cebi Y; Ersöz M; Cağatay P; Kiliçgedik M; Duman BS
Lipids Health Dis; 2008 Feb; 7():5. PubMed ID: 18298848
[TBL] [Abstract][Full Text] [Related]
19. Long-term atorvastatin improves age-related endothelial dysfunction by ameliorating oxidative stress and normalizing eNOS/iNOS imbalance in rat aorta.
Gong X; Ma Y; Ruan Y; Fu G; Wu S
Exp Gerontol; 2014 Apr; 52():9-17. PubMed ID: 24463049
[TBL] [Abstract][Full Text] [Related]
20. Effect of decreased plasma cholesterol by atorvastatin treatment on erythrocyte mechanical properties.
Uyuklu M; Meiselman HJ; Baskurt OK
Clin Hemorheol Microcirc; 2007; 36(1):25-33. PubMed ID: 17211059
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
